ProteoNic

Activities: Ingredients

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Proteonic unveils early access programme to elevate viral vector titers

Participants can achieve significant enhancements in titers, paving the way for increased viral vector production capacity and substantial improvements in manufacturing cost efficiency
Manufacturing

Proteonic and Ginkgo announce novel partnership

This strategic alliance will grant Ginkgo Bioworks’ customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications
Research & Development

Abzena Partners with ProteoNic to offer enhanced CHO cell line platform for complex biologics

Premium vector technology will improve the production of high-yielding mammalian cell lines
Manufacturing

CDMO and vector specialist join forces to improve VV production efficiency

ProteoNic and NecstGen have recognised the need to increase viral titres and optimise production processes in order to improve the feasibility of vector-based therapies
Subscribe now